BioCentury | May 11, 2020
Finance

Third Rock-backed fibrosis company Pliant joins IPO queue

Activity among biotech IPOs has reached a steady drip following a slowdown for several weeks as COVID-19’s spread roiled markets earlier this year. The latest to file for a NASDAQ listing is Pliant, a clinical...
BioCentury | Jul 18, 2018
Finance

Fibrosis firsts

Pliant Therapeutics Inc.’s preclinical models and discovery technology prompted Cowen Healthcare Investments and Menlo Ventures to choose the company as their first fibrosis investments. Cowen led Pliant’s untranched $62 million series B round on Monday,...
BioCentury | Jun 22, 2018
Financial News

Decibel raises $55M in series C, names Scangos chairman

Decibel Therapeutics Inc. (Boston, Mass.) raised $55 million on June 19 in a series C round from existing investors Third Rock Venture, GV, SR One and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and new investors Foresite Capital,...
BioCentury | Jun 19, 2018
Financial News

Decibel raises $55M in series C, names Scangos chairman

Decibel Therapeutics Inc. (Boston, Mass.) raised $55 million in a series C round from existing investors Third Rock Venture, GV, SR One and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and new investors Foresite Capital, Bessemer Venture Partners,...
BioCentury | Aug 18, 2014
Clinical News

Teysuno tegafur/gimeracil/oteracil potassium: Phase III data

The double-blind, Japanese Phase III S-CUBE trial in 334 patients with advanced HCC whose disease progressed after treatment with or who were intolerant to Nexavar sorafenib showed that S-1 missed the primary endpoint of improving...
BioCentury | Aug 14, 2014
Cover Story

Navigating the new road in psychiatry

The lack of predictive animal models for neuropsychiatric diseases is arguably the biggest single factor stifling drug development in the field. To kick-start discovery for diseases such as autism, schizophrenia and depression, stakeholders will need...
BioCentury | Feb 4, 2013
Company News

Trellis Bioscience management update

...San Francisco, Calif. Business: Antibodies, Infectious, Cancer Hired: Stephan Ryser as CEO, formerly CEO of A-CUBE Inc. WIR...
BioCentury | May 21, 2012
Strategy

Remembrance: The Titan who changed our lives

Remembrance: The Titan who changed our lives For those of us who entered the biotech industry in the 1980s, George Rathmann already was a living legend. And those of us who knew him consider ourselves...
BioCentury | Mar 28, 2011
Company News

A-CUBE, ProtevoBio deal

...The companies partnered to design and develop three second generation mAbs. A-CUBE said the partners will...
...the partners will share revenues generated from out-licensing the mAbs. Further terms were not disclosed. A-CUBE Inc....
BioCentury | Dec 20, 2010
Company News

A-CUBE, Roche deal

...use A-CUBE's in silico algorithms to develop next-generation antibody therapeutics. Further terms were not disclosed. A-CUBE Inc....
Items per page:
1 - 10 of 21
BioCentury | May 11, 2020
Finance

Third Rock-backed fibrosis company Pliant joins IPO queue

Activity among biotech IPOs has reached a steady drip following a slowdown for several weeks as COVID-19’s spread roiled markets earlier this year. The latest to file for a NASDAQ listing is Pliant, a clinical...
BioCentury | Jul 18, 2018
Finance

Fibrosis firsts

Pliant Therapeutics Inc.’s preclinical models and discovery technology prompted Cowen Healthcare Investments and Menlo Ventures to choose the company as their first fibrosis investments. Cowen led Pliant’s untranched $62 million series B round on Monday,...
BioCentury | Jun 22, 2018
Financial News

Decibel raises $55M in series C, names Scangos chairman

Decibel Therapeutics Inc. (Boston, Mass.) raised $55 million on June 19 in a series C round from existing investors Third Rock Venture, GV, SR One and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and new investors Foresite Capital,...
BioCentury | Jun 19, 2018
Financial News

Decibel raises $55M in series C, names Scangos chairman

Decibel Therapeutics Inc. (Boston, Mass.) raised $55 million in a series C round from existing investors Third Rock Venture, GV, SR One and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and new investors Foresite Capital, Bessemer Venture Partners,...
BioCentury | Aug 18, 2014
Clinical News

Teysuno tegafur/gimeracil/oteracil potassium: Phase III data

The double-blind, Japanese Phase III S-CUBE trial in 334 patients with advanced HCC whose disease progressed after treatment with or who were intolerant to Nexavar sorafenib showed that S-1 missed the primary endpoint of improving...
BioCentury | Aug 14, 2014
Cover Story

Navigating the new road in psychiatry

The lack of predictive animal models for neuropsychiatric diseases is arguably the biggest single factor stifling drug development in the field. To kick-start discovery for diseases such as autism, schizophrenia and depression, stakeholders will need...
BioCentury | Feb 4, 2013
Company News

Trellis Bioscience management update

...San Francisco, Calif. Business: Antibodies, Infectious, Cancer Hired: Stephan Ryser as CEO, formerly CEO of A-CUBE Inc. WIR...
BioCentury | May 21, 2012
Strategy

Remembrance: The Titan who changed our lives

Remembrance: The Titan who changed our lives For those of us who entered the biotech industry in the 1980s, George Rathmann already was a living legend. And those of us who knew him consider ourselves...
BioCentury | Mar 28, 2011
Company News

A-CUBE, ProtevoBio deal

...The companies partnered to design and develop three second generation mAbs. A-CUBE said the partners will...
...the partners will share revenues generated from out-licensing the mAbs. Further terms were not disclosed. A-CUBE Inc....
BioCentury | Dec 20, 2010
Company News

A-CUBE, Roche deal

...use A-CUBE's in silico algorithms to develop next-generation antibody therapeutics. Further terms were not disclosed. A-CUBE Inc....
Items per page:
1 - 10 of 21